Search results for " Drug"

showing 10 items of 3138 documents

Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

2016

Appropriate post-transplant immunosuppressive regimens that avoid acute rejection, while reducing risk of viral reactivation, have been sought, but remain a chimera. Recent evidence suggesting potential regulatory and antiviral effects of mammalian target of rapamycin inhibitors (mTORi) is of great interest. Although the concept of an immunosuppressive drug with antiviral properties is not new, little effort has been made to put the evidence together to assess the management of immunosuppressive therapy in the presence of a viral infection. This review was developed to gather the evidence on antiviral activity of the mTORi against the viruses that most commonly reactivate in adult solid org…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentHepatitis C virus030230 surgerymedicine.disease_causeAntiviral AgentsOrgan transplantationVirus03 medical and health sciencesChimera (genetics)0302 clinical medicinemedicineHumansImmunosuppression TherapyTransplantationEverolimusbusiness.industryTOR Serine-Threonine Kinasesvirus diseasesImmunosuppressionOrgan TransplantationTransplant RecipientsInfectious DiseasesImmunosuppressive drugVirus DiseasesSirolimusImmunology030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct

DNA damage by bromate: Mechanism and consequences

2005

Abstract Exposure of mammalian cells to bromate (BrO3−) generates oxidative DNA modifications, in particular 7,8-dihydro-8-oxo-guanine (8-oxoG). The damaging mechanism is quite unique, since glutathione, which is protective against most oxidants and alkylating agents, mediates a metabolic activation, while bromate itself does not react directly with DNA. Neither enzymes nor transition metals are required as catalysts in the activation. The ultimate DNA damaging species has not yet been established, but experiments under cell-free conditions suggest that neither molecular bromine nor reactive oxygen species such as superoxide, hydrogen peroxide or singlet oxygen are involved. Rather bromine …

GuanineCell SurvivalDNA damageHypochloriteToxicologymedicine.disease_causeMicechemistry.chemical_compoundCricetulusCell Line TumorCricetinaemedicineAnimalsHydrogen peroxideMicronuclei Chromosome-Defectivechemistry.chemical_classificationReactive oxygen speciesMicronucleus TestsDose-Response Relationship DrugBromatesSinglet oxygenSuperoxideBromatechemistryBiochemistryReactive Oxygen SpeciesOxidative stressDNA DamageMutagensToxicology
researchProduct

Ruthenium-arene complexes bearing naphthyl-substituted 1,3-dioxoindan-2-carboxamides ligands for G-quadruplex DNA recognition.

2019

Quadruplex nucleic acids – DNA/RNA secondary structures formed in guanine rich sequences – proved to have key roles in the biology of cancers and, as such, in recent years they emerged as promising targets for small molecules. Many reports demonstrated that metal complexes can effectively stabilize quadruplex structures, promoting telomerase inhibition, downregulation of the expression of cancer-related genes and ultimately cancer cell death. Although extensively explored as anticancer agents, studies on the ability of ruthenium arene complexes to interact with quadruplex nucleic acids are surprisingly almost unknown. Herein, we report on the synthesis and characterization of four novel Ru(…

GuanineStereochemistryCell Survivalchemistry.chemical_elementAntineoplastic Agents010402 general chemistryG-quadruplexLigands01 natural sciencesRutheniumInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipCoordination ComplexesPyridineTumor Cells CulturedHumansRuthenium Quadruplex G-quadruplex G4 DNA Cancer Metal Complexesheterocyclic compoundsCell ProliferationDose-Response Relationship DrugMolecular Structure010405 organic chemistryLigandRNASmall molecule3. Good health0104 chemical sciencesRutheniumG-QuadruplexeschemistrySettore CHIM/03 - Chimica Generale E InorganicaCalixarenesDrug Screening Assays AntitumorDNADalton transactions (Cambridge, England : 2003)
researchProduct

Dydrogesterone use during pregnancy: Overview of birth defects reported since 1977

2009

Between 1977 and 2005, 28 cases of potential links between maternal dydrogesterone use during pregnancy and congenital birth defects were reported. The types of defects were very diverse, with no evidence of a pattern of abnormalities. The data do not provide evidence for congenital malformations associated with dydrogesterone use.

Gynecologymedicine.medical_specialtyPregnancyProgestogenObstetricsbusiness.industrymedicine.medical_treatmentAbnormalities Drug-InducedObstetrics and GynecologyCongenital malformationsDydrogesteronemedicine.diseaseMaternal ExposurePregnancyPediatrics Perinatology and Child HealthDydrogesteronemedicineAdverse Drug Reaction Reporting SystemsHumansGestationFemaleProgestinsbusinessmedicine.drugEarly Human Development
researchProduct

Triterpenoid saponins from the roots of two Gypsophila species.

2013

Two triterpenoid saponins with two known ones have been isolated from the roots of Gypsophila arrostii var. nebulosa, and two new ones from the roots of Gypsophila bicolor. Their structures were established by extensive NMR and mass spectroscopic techniques as 3-O-β-d-galactopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→3)]-β-d-glucuronopyranosylquillaic acid 28-O-β-d-xylopyranosyl-(1→4)-[β-d-glucopyranosyl-(1→3)]-α-l-rhamnopyranosyl-(1→2)-[β-d-glucopyranosyl-(1→4)]-β-d-fucopyranosyl ester (1), 3-O-β-d-galactopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→3)]-β-d-glucuronopyranosylgypsogenin 28-O-β-d-xylopyranosyl-(1→4)-[β-d-glucopyranosyl-(1→3)]-α-l-rhamnopyranosyl-(1→2)-[β-d-glucopyranosyl-(1→4)]-β-d-fuco…

Gypsophila arrostiiGypsophilaStereochemistryCell SurvivalMolecular ConformationStereoisomerismAntineoplastic AgentsCaryophyllaceaePlant ScienceHorticultureBiochemistryPlant RootsCell LineTerpeneStructure-Activity RelationshipTriterpenoidSpecies SpecificityAnimalsHumansMolecular BiologyCell ProliferationPlant rootsbiologyDose-Response Relationship DrugChemistryStereoisomerismGeneral MedicineSaponinsbiology.organism_classificationTriterpenesRatsHuman colon cancerDrug Screening Assays AntitumorTwo-dimensional nuclear magnetic resonance spectroscopyPhytochemistry
researchProduct

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient dat…

2002

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies. Methods: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Retreatment with various IFN schedules (mean total dose 544 mega units) and a fixed ribavirin dose (1000–1200 mg/daily depending on body weight) was given for 24–60 (mean 39.5) weeks. Results: Biochemical …

HCV interferon ribavirinAdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentAlpha interferonGastroenterologyAntiviral AgentsDrug Administration Schedulechemistry.chemical_compoundDrug TherapyInternal medicineRibavirinmedicineHumansImmunologic FactorsTreatment FailureChronicAdverse effectChemotherapyAdult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy; Combination; Female; Hepatitis C; Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure; gamma-GlutamyltransferaseChi-Square Distributionbusiness.industryRibavirinLiver DiseaseGastroenterologyInterferon-alphaHepatitis Cgamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CConfidence intervalhumanitiesSurgeryLogistic ModelschemistryTolerabilityCombinationDrug Therapy CombinationFemalebusiness
researchProduct

Prevalenza di infezione da virus erpetico di tipo 8 (HHV8) in tossicodipendenti afferenti ai Servizi Pubblici per il Trattamento delle Tossicodipende…

2006

HHV8injecting drug user
researchProduct

Synthesis and induction of G0–G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazep…

2007

The multistep synthesis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one 15 has been carried out. The compound showed antiproliferative and apoptotic effects against K562, K562-R (imatinib mesilate resistant), HL60 and multidrug resistant (MDR) HL60 cell lines. Compound 15 showed a pro-apoptotic activity against HL60 and K562 resistant cell lines markedly higher than etoposide and busulfan, respectively. Flow cytometry studies carried out on K562 cells allowed to establish that 15 induces G0-G1 phase arrest followed by apoptosis.

HL60StereochemistryApoptosisHL-60 CellsAntiproliferative activityResting Phase Cell CycleChemical synthesisPyrazolo[34-f][1234]tetrazepinoneFlow cytometrychemistry.chemical_compoundhemic and lymphatic diseasesDrug DiscoverymedicineHumansCytotoxicityEtoposideG0-G1 arrestPharmacologyTrifluoromethylMolecular Structuremedicine.diagnostic_testOrganic ChemistryG1 PhaseApoptosiAzepinesGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaMolecular biologyMultiple drug resistancechemistryApoptosisDrug resistancePyrazoles1234-TetrazepinoneK562 Cellsmedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

Caratterizzazione e valutazione dell’attività anti proliferativa di nuovi sistemi per il drug carrier Allosite-sali triazolici/cardanolo

2014

Da precedenti studi è stato valutato che i nanotubi di allosite modificati con sali triazolici (f-HNT), sono dei promettenti sistemi carrier per molecole biologiche1. In questo lavoro si riportano i risultati ottenuti studiando gli f-HNT come carrier per il cardanolo, molecola con interessanti attività biologiche. L’interazione fra il cardanolo e gli f-HNT è stata valutata tramite HPLC, spettroscopia FTIR, analisi termogravimentrica, misure di angolo di contatto e microscopia a scansione elettronica. Infine sono stati studiati sia il rilascio del cardanolo dal sistema che gli effetti citotossici del complesso f-HNT/Cardanolo verso linee cellulari di epatocarcinoma. I dati sperimentali otten…

HNT cardanolo epatocarcinoma drug carrier.Settore BIO/14 - FarmacologiaSettore CHIM/06 - Chimica OrganicaSettore CHIM/02 - Chimica Fisica
researchProduct

NEW BIODEGRADABLE HYDROGELS DESIGNED FOR COLONIC DRUG DELIVERY: IN VITRO RELEASE OF THE PEPTIDES GLUTATHIONE AND OXYTOCIN

2009

HYDROGELS DRUG DELIVERY.Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
researchProduct